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Background: Feasibility of whole breast hypofractionated radiotherapy schedules in breast conserving therapy is
recognized however concerns remain about the role of the boost dose on the overall treatment’s potential toxicity.
In this study we report on the possibility to quantitatively evaluate radiation induced toxicity in patients treated
with an abbreviated course with major concern in the irradiated boost region.
Methods: Eighty-nine patients who underwent conservative surgery for early-stage breast cancer followed by
adjuvant accelerated hypofractionated whole breast radiotherapy were included in this study to assess skin and
subcutaneous tissue late toxicity by means of ultrasonographic quantitative examination. For each patient the skin
thickness was measured at four positions: on the irradiated breast, in the boost region and in the corresponding
positions in the contra-lateral not treated breast. All patients were scanned by the same radiologist to reduce
potential inter-operator variability, the operator was blind to the scoring of the patient CTCv3 late toxicity as well as
patient treatment characteristics. Ultrasound assessment and clinical evaluation were compared.
Results: The median time between the end of adjuvant radiotherapy and ultrasound examination was
20.5 months. The measured mean skin thickness in the irradiated breast was 2.13 ± 0.72 mm while in the mirror
region of the contra-lateral healthy breast was 1.61 ± 0.29 mm. The measured mean skin thickness in the irradiated
boost region was 2.25 ± 0.79 mm versus 1.63 ± 0.33 mm in the corresponding region of contra-lateral healthy
breast. The mean increment in skin thickness respect to the counterpart in the healthy breast was 0.52 ± 0.67 mm
and 0.62 ± 0.74 mm for the breast and the boost region respectively. A significant direct correlation was found
between the increment in skin thickness in the irradiated breast and in the boost region with fibrosis (G ≥ 1).
Conclusions: In this study results from a breast cancer hypofractionated schedule in terms of late skin toxicity are
reported. In particular our study confirms that late cutaneous reactions can be reliably assed by ultrasonographic
examination, also discriminating between regions irradiated at different doses, and that this instrumental evaluation
is in agreement with clinical stated toxicity.
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Several phase III randomized clinical trials [1-3] have
evaluated the issue of hypofractionation in breast cancer
showing that hypofractionated adjuvant whole breast
radiotherapy (WBRT) after breast-conserving surgery
offers disease control rates and toxicity profiles equiva-
lent to those seen with normofractionated approach.* Correspondence: landoni@ifo.it
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stated.Based on long-term results from these studies there is,
therefore, a mature body of data supporting, as level I
evidence, selected whole breast hypofractionated radio-
therapy schedules in breast conserving therapy (BCT).
However concerns remain about the role of the boost
dose in hypofractionated fashion on the overall treat-
ment’s potential toxicity.
In the aforementioned randomized trials, in fact, none
[1] or only about 50% [2,3] of the patients received a
boost dose to the tumor bed but always with a normo-
fractionated approach (i.e., at 2 Gy/fr to a total dose ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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[4-7] reported on accelerated schedules of WBRT with
concomitant boost in prospective or retrospective studies.
In October 2004 we began a phase II prospective clinical
trial using an accelerated hypofractionated radiotherapy
schedule consisting of 10 daily fractions of 3.4 Gy to whole
breast plus a boost dose of 8 Gy in a single fraction in
patients who underwent breast conserving surgery for
early-stage breast cancer and who refused adjuvant con-
ventional radiotherapy regimen (50 Gy in 25 daily frac-
tions to the whole breast followed by 10–16 Gy in 5–8
daily fractions to the tumour bed) [4]. To quantitatively
evaluate skin radiation induced late toxicity after an abbre-
viated course, with major concern in the irradiated boost
region, patients underwent an ultrasonographic exami-
nation. In this article we report late normal-tissue toxicity
assessment by a quantitative ultrasound technique and its
relationship with clinical evaluation in the affected breast,
as well the comparison with the contra-lateral healthy not
irradiated one, after a minimum follow-up of 11.4 months.
The analysis was performed in a cohort of patients who,




Eighty-nine out of 152 patients who underwent conserva-
tive surgery for early-stage breast cancer (pTis, pT1-2,
pN0-1) and who adhered, between October 2004 and
December 2010, to our adjuvant accelerated hypofrac-
tionated whole breast radiotherapy prospective clinical
trial were included in this study to assess skin and sub-
cutaneous tissue late toxicity by means of quantitative
ultrasonographic examination. The radiotherapy schedule
consisted of 34 Gy in 10 daily fractions over 2 weeks to
the whole breast, followed by an electron boost dose of
8 Gy in a single fraction to the tumour bed. Exclusion
criteria included, pathologic diameter of primary > 3 cm,
the need for radiotherapy to regional lymph nodes, prior
breast or thoracic radiotherapy for any condition, syn-
chronous or metacronous bilateral invasive or non-invasive
breast cancer, age less than 18 years. The protocol has
been approved by the local Ethics and Scientific Com-
mittee. All patients provided a written informed consent.
Out of 89 patients, 36 (40%) were treated with adjuvant
chemotherapy before radiotherapy, either with CMF
(cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2,
5-FU 600 mg/m2 d 1 and d8 q 4 weeks × 6) in 7 patients
or FEC ( 5-FU 600 mg/m2, epirubicin 60 mg/m2, cyclo-
phosphamide 600 mg/m2 d 1 q 3 weeks × 6) in 12 pa-
tients or EC (epirubicin 60 mg/m2, cyclophosphamide
600 mg/m2 d1 q 3 weeks × 4) followed by Docetaxel
100 mg/m2 d1 q 3 weeks × 4) in 17 patients. The adjuvant
chemotherapy had generally been completed 3 to 4 weeksbefore starting radiotherapy. Adjuvant hormonotherapy,
with tamoxifen (associated with luteinizing hormone-
releasing hormone analogue in 1 patient) or anastrozole,
or letrozole, if indicated, was given simultaneously with
radiotherapy.
Radiation therapy
Details of radiotherapy treatment and the radiobiological
considerations were fully described in a previous paper
[8]. Briefly 3D conformal radiotherapy was delivered by
two opposed 6MV photon beams. Wedge compensation
was used to ensure a uniform dose distribution to the tar-
get volume of −5% and +7% [9]. No bolus was positioned
on the patient skin. The total dose was 34 Gy delivered in
10 daily fractions, 3.4 Gy per day, 5 days a week; the dose
was normalized at the ICRU (International Commission
on Radiation Units and Measurements) reference point
[9]. The boost dose of 8 Gy (prescribed to the 90% refe-
rence isodose) was administered, after one week in a sin-
gle fraction with electrons. Electron beam energy (range 6
to 12 MeV) was chosen according to tumour bed depth
and thickness indentified by metallic clips purposefully
positioned at the surgery time and/or by computer tomo-
graphy images. Our schedule of 34 Gy in 10 fractions plus
a boost of 8 Gy in one fraction is biologically equivalent
(in respect of 2 Gy/fr conventional radiotherapy approach)
to 47–53 Gy for whole breast and 59–70 Gy considering
the tumour boost volume, according to an α/β range
values from 4.6 to 10 Gy.
Clinical toxicity assessment
Scale used to score toxicity was the National Cancer
Institute Common Toxicity Criteria for Adverse Events
version 3.0 (CTVv3) for skin and subcutaneous indu-
ration/fibrosis [10]. Effects of radiation therapy on skin
and subcutaneous tissue were graded on 0 to 3 with G0
indicating no toxic effects, G1 = increased density on pal-
pation, G2 =marked increase in density and firmness on
palpation with or without minimal retraction, G3 = very
marked density, retraction or fixation. Clinical toxicity
assessment was performed the same day of instrumental
exam by a radiation oncologist not involved in the ultra-
sonographic session.
Ultrasonographic examination
Patients laid in supine position. A thin layer of ultra-
sound transmission gel was used to ensure good coup-
ling between the skin and the probe. The axis of the
transducer was kept perpendicular to the surface of the
skin and the slightest possible force was applied to avoid
affecting the skin thickness measurement. Four to six
ultrasound scans were obtained for each region (radial
and vertical). The boost region was identified from a
picture of the radiotherapy field taken at the time of
Figure 1 The full thickness, epidermis plus dermis was measured on the irradiated breast, in the boost region and in the
corresponding positions in the contra-lateral not treated breast.
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10–15 minutes. Images were acquired in B-mode using a
Sequoia 512 scanner (Siemens Medical Systems, USA)
with a linear transducer array transducer (15 L8 W). Fre-
quency: 8.0 - 15.0 MHz. A “Breast protocol” was applied
for imaging with the following characteristics: dynamic
range was 68 dB, that allows optimal differentiation
between subtle changes in echo intensities in the skin
region, overall gain was set to 18 dB, Delta was Δ2 for
high contrast resolution, focal zone was always placed so
to optimize lateral resolution at the level of the skin.
The full thickness, epidermis plus dermis was measured
(Figure 1). Measurements were performed at four posi-
tions for each patient: on the irradiated breast at 34 Gy
(A), on the irradiated breast in the boost region at 42 Gy
(34 Gy whole breast + 8 Gy boost) (B), and in the cor-
responding positions in the contra-lateral not treated
healthy breast (A’) and (B’). See Figure 2. All imagesFigure 2 Diagram of the location of the ultrasound
measurements. A corresponds to the irradiated breast at 34 Gy,
B corresponds to the boost region at 42 Gy, A’ and B’ correspond
to the mirror positions in the contra-lateral healthy breast.were stored on disk for further analysis. All patients
were scanned by the same radiologist to reduce potential
inter-operator variability, the operator was blind to the
scoring of the patient CTCv3 late toxicity as well as
patient treatment characteristics.
Statistical analysis
A t-test for independent samples was used to evaluate
the correlation between skin thickness in the irradiated
region and in the same region of the contralateral breast
(A vs A’), the same was performed between skin thick-
ness in the boost region and in the same region of the
contralateral breast (B vs B’). Also a t-test for paired
samples was used to evaluate the correlation between
skin thickness in the boost region and in the non boost
region in the irradiated breast (B vs A). To investigate
the correlation between skin thickness and clinical and
dosimetric variables measured the Pearson correlation
coefficient and the Spearman correlation coefficient were
calculated for continuous and ordinal variables respec-
tively. A t test was then performed to state the sig-
nificance of the correlation. For all the analysis the
correlation was considered significant if p < 0.05.
Results
Patient and tumour main characteristics are shown in
Table 1.
All the patients were Caucasian. Patients’ median age
was 62 years (range 31–79). Of the 89 patients included in
the analysis, 37 had axillary nodes dissection and 52 had a
sentinel lymph node biopsy. 36 patients (40%) received
systemic chemotherapy, 68 (76%) hormonal therapy, and
23 (26%) patients received both. 8 (9%) patients received
no adjuvant systemic therapy. Skin and subcutaneous
toxicity scores as assessed at the same time of ultraso-
nographic examination are presented in Figure 3. A total
of 13 patients (14.6%) developed at that time Grade ≥ 1
Table 1 Patients and tumour characteristics
Age (years) Median 62 (31–79)




pT2 (≤3 cm) 11
pN stage
pN0 70











Follow-up (months) 20.5 (11.4-85.7)
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The time elapsed between the end of adjuvant radio-
therapy and ultrasound examination ranged from 11.4 to
85.7 months (mean: 33.5, median: 20.5, standard devia-
tion: 24.2). The measured mean skin thickness in theFigure 3 Percentage incidence of late skin toxicity.irradiated breast at 34 Gy (A) was 2.13 ± 0.72 mm while in
the mirror region of the contra-lateral healthy breast (A’)
was 1.61 ± 0.29 mm. The measured mean skin thickness
in the irradiated boost region at 42 Gy (B) was 2.25 ±
0.79 mm versus 1.63 ± 0.33 mm in the corresponding
region of contra-lateral healthy breast (B’). The mean
increment in skin thickness respect to the counterpart
in the healthy breast was 0.52 ± 0.67 mm and 0.62 ±
0.74 mm for the irradiated breast at 34 Gy and the boost
region respectively. Differences in skin thickness measured
in the boosted area (region B in Figure 2) and in the irra-
diated breast at 34 Gy (region A in Figure 2) were not
significant. In Figure 4 data comparison for the measure-
ments of skin thickness between treated and untreated
breast are shown for both the irradiated breast and the
boost region; differences in skin thickness were statistically
significant (p < 0.001) for both examined regions. As ex-
pected the correlation between the increment in skin
thickness in the boost region and the increment in skin
thickness in the breast region resulted statistically signifi-
cant (p = 0.0117). To assess the relevance of these data we
investigated whether skin thickening as measured by
ultrasonographic examination correlates with CTCv3 eva-
luation of radiation induced skin and subcutaneous tissue
indurations/fibrosis. A significant direct correlation was
found between the increment in skin thickness in the irra-
diated breast and in the boost region with fibrosis (G ≥ 1),
with a p value of 0.0236 and 0.0164 respectively. In agree-
ment with the correlation above reported we found that in
the irradiated breast region the average increase in skin
thickness was 32% among patients with Grade 0 fibrosis
Figure 4 Box and whisker plot for data comparison of measured skin thickness between treated and untreated breast; differences
were statistically significant. A corresponds to the irradiated breast, B corresponds to the boost region, A’ and B’ correspond to the mirror
positions in the contra-lateral healthy breast.
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the boost region the average increase in skin thickness
was 36% among patients with Grade 0 fibrosis and 56%
among patients with Grade ≥ 1 fibrosis. The increment in
skin thickness (%) in the boost and in the irradiated breast
region for the different levels of toxicity is reported in
Figure 5. Results of the evaluation of the role of previous
adjuvant chemotherapy and/or concomitant hormonal
therapy on skin thickening are shown in Figure 6. No sig-
nificant correlation was found between skin thickening
and systemic therapies, in particular for skin thickening in
the treated breast at 34 Gy and in the boost region p wasFigure 5 Increment in skin thickness (%) in the boost (O) and in the i
grades of toxicity.0.340 and 0.411 for chemotherapy and 0.259 and 0.729 for
hormonotherapy.
Discussion
Several phase III randomized clinical trials [1-3] have eva-
luated the issue of hypofractionation in early-stage breast
cancer showing that hypofractionated adjuvant whole
breast radiotherapy after breast-conserving surgery offers
equivalent results to those seen with normo-fractionated
approach also representing an attractive treatment option
because it allows for the shortened course of adjuvant RT.
However concerns remain about the role of the boostrradiated breast (⁮) region (the 34 Gy region) for the different
Figure 6 Scatter diagram of the correlation between previous
adjuvant chemotherapy and/or concomitant hormonal therapy
on skin thickenings.
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potential toxicity to such an extent that the ASTRO task
force, who in 2011 developed an evidence-based guideline
to provide direction for whole breast hypofractionation in
clinical practice, did not reach unanimous consensus re-
garding a specific dose-fractionation scheme to use for
the boost dose, therefore the ASTRO task force con-
cluded that “on the basis of the published data and the
collective expert opinion of the panel, boost doses of
10–16 Gy in 2-Gy fractions or 10 Gy in 2.5-Gy fractions
were considered acceptable” [11]. On the other hand in
the three randomized trials that contributed to clarify the
role of hypofractionation in adjuvant whole breast radio-
therapy the boost dose to the tumor bed was not pre-
scribed [1] or was administered (at discretion of physician
or according to local indications) in percentage ranging
between 42% [2] and 60% [3] always at 2 Gy/fr to a total
dose of 10 Gy in five fractions. In addiction the impact of
boost dose on late toxicity was not separately analyzed. In
our study 14% of patients developed ≥G1 late toxicity, this
result being in accordance with other published data [12].
Skin fibrosis is a common radiation-induced late effect
usually scored by means of eye and palpation-based rating
scales that are inevitably affected by examining physician
subjective judgment with possible intra ed inter-obsever
variability, the same is for cosmetic results or change in
breast appearance judged using different, sometimes
homemade, scoring systems. In fact the application of dif-
ferent toxicity scoring scales, in conjunction with the pos-
sibility of a subjective interpretation of clinical toxicity
data, based on visual and tactile examinations, might ex-
plain discrepancies in toxicity results between different
studies. H. Alexander et al. [13] in 1979 first reported onhigh frequency, high resolution ultrasonic echo technique
as an accurate simple and noninvasive method for meas-
uring full-thickness human skin. Recently T. Liu et al
[14,15] have pointed out the role of high frequency ultra-
sound imaging as a reliable tool to assess late skin toxicity
after breast radiotherapy also by change of skin thickness
as a objective measure of the severity of fibrosis. Of note
our study is the first one on the late skin toxicity assess-
ment by quantitative ultrasonographic analysis after accel-
erated hypofractionated radiotherapy in women who
underwent breast conserving surgery. Moreover in our co-
hort we analyzed whole breast as well as boost area radi-
ation–induced late skin toxicity by quantitative
ultrasonographic analysis through the correlation between
skin thickness in the two “dose-levels” irradiated region (i.
e., whole breast and boost area) and the mirror regions of
the contralateral not irradiated healthy breast. In the paper
by T. Liu et al [16] the ultrasonographic evaluation of ra-
diation induced toxicity is reported in terms of skin thick-
ness, Pearson coefficient and midband fit and the three
parameters are said to be able to measure toxicity and cor-
relate with the clinically RTOG scored one [17]. In our
study only skin thickness was measured by ultrasonog-
raphy and toxicity was scored with CTCv3 scale. Never-
theless our results are in agreement with the previous
reported pilot study of breast cancer radiotherapy in
which authors state that there is a “good correlation be-
tween skin thickness measurements and clinical assess-
ment, suggesting this parameter’s ability to measure
dermal injury”. Ultrasonographic examination was also
used to try to clarify the role of boost dose with
hypofractionated approach on late skin toxicity evaluating
the burden of a single high boost-dose by means measure-
ments of skin thickness in the boost region and in the non
boost region of the irradiated breast. To the best of our
knowledge none of study on high frequency ultrasound
imaging as a consistent instrument to assess late radio-
therapy skin toxicity have focused its attention on boost
area. In our cohort there was no significant difference in
skin thickness between boost (“42 Gy irradiated area”) and
no boost region (“34 Gy irradiated area”) of the affected
breast. So that it seems that the additional boost in a
single high dose fraction does not contribute to enhance
fibrosis detectable through an increase in skin thickness.
This result could perhaps contribute to better define the
feasibility of boost dose administration with hypofrac-
tionated approach. The authors recognize that a possible
limitation of their study could be that the time between
the end of radiotherapy and the ultrasonographic exami-
nation vary widely among patients but a minimum follow
up of about 1 year was considered enough for late skin
toxicity to be initially expressed. Another issue is whether
the previous adjuvant chemotherapy, specially modern
anthracycline-based and taxane-based regimes, as well as
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worse fibrosis and adverse cosmesis. The effect of hypo-
fractionation on cosmetic outcome and fibrosis in women
who received this adjuvant systemic therapy was not sepa-
rately assessed in the three prospective randomized trials
mentioned above. T Hijal et al. [18] in a single-centre
retrospective analysis reported that the rates of late skin
toxicity were not significantly different in respect of adju-
vant chemotherapy. In our cohort 38/89 patients received
chemotherapy (mostly anthracycline-based and taxane-
based regimes) before hypofractionated whole breast
radiotherapy and no correlation was found between skin
thickening and previous systemic therapies.
Conclusion
Our study confirms that late toxicity evaluation by means
of US is feasible, easy, not expensive and not highly time
consuming and that is in agreement with clinical assed
toxicity suggesting its widespread especially when patients
are treated with new schedules of breast radiotherapy. In
particular, as the use of hypofractionation increases and
more and more frequently new schedules are tested in
adjuvant WBI prospective trials, it could be crucial to have
a quantitative easy reproducible tool for assessing and
documenting late cutaneous reaction not affected by
intra- and inter-observer variation in adjunct to physical
examination based on eye and/or palpation. The results of
the study in progress by Liu et al [14] on a breast cancer
population “in which specific locations, such as the boost
regions, will be separately examined” and the proposed
investigation on hypofractionaction might confirm our
conclusions. If this will be the case, giving a quantitative
measure of toxicity and being possible to revaluate images,
because stored and documented, this technique good play
an important role in multicentric studies where using the
same “language” should be encouraged.
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